{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:10:06Z","timestamp":1779433806422,"version":"3.53.1"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"abstract":"<jats:p>\n                    Neuromyelitis optica spectrum disorder (NMOSD) is a rare central nervous system autoimmune disease, predominantly marked by optic neuritis and transverse myelitis. In addition to its significant physical burden, NMOSD is associated with psychological challenges, including stigma, which remains underexplored. This study aimed to investigate the stigmatization and its associations with demographic, clinical, and psychological characteristics in people with NMOSD (PwNMOSD). This cross-sectional study recruited 80 PwNMOSD in Isfahan, Iran. Data on demographic, clinical, and psychological features and quality-of-life (QoL) were obtained using medical records, neurological examinations, and standardized instruments. General linear models were employed to assess the relationships between stigma and demographic, clinical, or psychological variables. Stigma was significantly and independently associated with increased disability (Expanded Disability Status Scale, \u03b2\u2005=\u20051.34,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002), impaired mobility (Timed 25-Foot Walk test (T25FW), \u03b2\u2005=\u20051.48,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), depression (\u03b2\u2005=\u20050.21,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006), and reduced QoL (\u03b2\u2005=\u20050.17,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Higher levels of stigma correlated with increased psychological distress and physical impairment. NMOSD-related stigma was strongly linked to disability, depression, and QoL, highlighting the need for targeted interventions. Addressing stigma through psychological and rehabilitative strategies may improve the well-being of PwNMOSD. Future longitudinal studies need to validate these findings.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046738","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T04:02:37Z","timestamp":1766203357000},"page":"e46738","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The impact of physical and psychological health outcomes on stigma in people with neuromyelitis optica spectrum disorder: A cross-sectional study"],"prefix":"10.1097","volume":"104","author":[{"given":"Aysa","family":"Shaygannejad","sequence":"first","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Yazdan Panah","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Vaheb","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Afshari-Safavi","sequence":"additional","affiliation":[{"name":"Addiction and Behavioral Sciences Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran"},{"name":"Department of Biostatistics and Epidemiology, School of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6960-1265","authenticated-orcid":false,"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260522","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis.","volume":"9","author":"Borisow","year":"2018","journal-title":"Front Neurol"},{"key":"R2-20260522","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients.","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler"},{"key":"R3-20260522","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jocn.2010.12.052","article-title":"Prominent brainstem symptoms\/signs in patients with neuromyelitis optica in a Taiwanese population.","volume":"18","author":"Wang","year":"2011","journal-title":"J Clin Neurosci"},{"key":"R4-20260522","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/B978-0-323-98817-9.00020-X","article-title":"Transverse myelitis in children and adults.","volume":"196","author":"Grasso","year":"2023","journal-title":"Handb Clin Neurol"},{"key":"R5-20260522","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG\u2013positive neuromyelitis optica spectrum disorders.","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"key":"R6-20260522","doi-asserted-by":"crossref","first-page":"101487","DOI":"10.1016\/j.msard.2019.101487","article-title":"The frequency of longitudinally extensive transverse myelitis in MS: a population-based study.","volume":"37","author":"Asnafi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R7-20260522","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"R8-20260522","doi-asserted-by":"crossref","first-page":"106465","DOI":"10.1016\/j.msard.2025.106465","article-title":"Radiomics-based analysis of choroid plexus abnormalities in neuromyelitis optica spectrum disorders and multiple sclerosis and their clinical implications.","volume":"99","author":"Wang","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"R9-20260522","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis. Article.","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R10-20260522","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neurol.2016.03.003","article-title":"Neuromyelitis optica spectrum disorder (NMOSD): a new concept.","volume":"172","author":"De Seze","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"R11-20260522","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R12-20260522","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide.","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"R13-20260522","doi-asserted-by":"crossref","first-page":"104654","DOI":"10.1016\/j.nurpra.2023.104654","article-title":"Neuromyelitis optica spectrum disorder: an early diagnosis to prevent blindness and paraplegia.","volume":"19","author":"George","year":"2023","journal-title":"J Nurse Pract"},{"key":"R14-20260522","doi-asserted-by":"crossref","first-page":"e0300777","DOI":"10.1371\/journal.pone.0300777","article-title":"The psychological burden of NMOSD \u2013 a mixed method study of patients and caregivers.","volume":"19","author":"Esiason","year":"2024","journal-title":"PLoS One"},{"key":"R15-20260522","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40120-022-00356-6","article-title":"Impact of neuromyelitis optica spectrum disorder on quality of life from the patients\u2019 perspective: an observational cross-sectional study.","volume":"11","author":"Meca-Lallana","year":"2022","journal-title":"Neurol Ther"},{"key":"R16-20260522","first-page":"2055217319852717","article-title":"Perception of stigma in patients with primary progressive multiple sclerosis.","volume":"5","author":"P\u00e9rez-Miralles","year":"2019","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"R17-20260522","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12883-024-03853-3","article-title":"Stigma and health outcomes in multiple sclerosis: a systematic review.","volume":"24","author":"Powell","year":"2024","journal-title":"BMC Neurol"},{"key":"R18-20260522","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/AUD.0000000000001398","article-title":"The self-stigma of hearing loss in adults and older adults: a systematic review.","volume":"44","author":"da Silva","year":"2023","journal-title":"Ear Hear"},{"key":"R19-20260522","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/PPA.S305707","article-title":"Perception of stigma in patients with neuromyelitis optica spectrum disorder.","volume":"15","author":"Meca-Lallana","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"R20-20260522","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7224\/1537-2073.2023-047","article-title":"Stigma in multiple sclerosis: a narrative review of current concepts, measures, and findings.","volume":"26","author":"Winston-Khan","year":"2024","journal-title":"Int J MS Care"},{"key":"R21-20260522","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-024-03544-z","article-title":"Validity and reliability of the Persian version of Recce stigma scale in people with multiple sclerosis and its impact on quality of life.","volume":"24","author":"Habibi","year":"2024","journal-title":"BMC Neurol"},{"key":"R22-20260522","doi-asserted-by":"crossref","first-page":"104591","DOI":"10.1016\/j.msard.2023.104591","article-title":"The impact of stigma on perceived quality of life and experience of anxiety and depression in individuals diagnosed with MS.","volume":"72","author":"Tworek","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"R23-20260522","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.3390\/ijms22168638","article-title":"Treatment of neuromyelitis optica spectrum disorders.","volume":"22","author":"Chan","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R24-20260522","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/ene.15355","article-title":"Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.","volume":"29","author":"Huang","year":"2022","journal-title":"Eur J Neurol"},{"key":"R25-20260522","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40120-021-00298-5","article-title":"Effective rituximab treatment in patients with neuromyelitis optica spectrum disorders compared with azathioprine and mycophenolate.","volume":"11","author":"Yang","year":"2022","journal-title":"Neurol Ther"},{"key":"R26-20260522","doi-asserted-by":"crossref","first-page":"102869","DOI":"10.1016\/j.msard.2021.102869","article-title":"Effectiveness of treatments in neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.","volume":"50","author":"Velasco","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R27-20260522","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"R28-20260522","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"R29-20260522","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.","volume":"385","author":"Yang","year":"2018","journal-title":"J Neurol Sci"},{"key":"R30-20260522","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/jcm9051326","article-title":"Clinical characteristics and disability progression of early-and late-onset multiple sclerosis compared to adult-onset multiple sclerosis.","volume":"9","author":"Mirmosayyeb","year":"2020","journal-title":"J Clin Med"},{"key":"R31-20260522","doi-asserted-by":"crossref","first-page":"111210","DOI":"10.1016\/j.jocn.2025.111210","article-title":"Clinical and psychological factors associated with fear of relapse in people with multiple sclerosis: A cross-sectional study.","volume":"135","author":"Ghaffary","year":"2025","journal-title":"J Clin Neurosci"},{"key":"R32-20260522","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"R33-20260522","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"R34-20260522","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/153944928500500102","article-title":"Adult norms for the nine hole peg test of finger dexterity.","volume":"5","author":"Mathiowetz","year":"1985","journal-title":"Occup Ther J Res"},{"key":"R35-20260522","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/1352458517690823","article-title":"Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.","volume":"23","author":"Motl","year":"2017","journal-title":"Mult Scler"},{"key":"R36-20260522","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1191\/1352458502ms845oa","article-title":"The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials.","volume":"8","author":"Rudick","year":"2002","journal-title":"Mult Scler J"},{"key":"R37-20260522","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.","volume":"23","author":"Feys","year":"2017","journal-title":"Mult Scler"},{"key":"R38-20260522","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.apmr.2015.12.031","article-title":"Validity of the timed up and go test as a measure of functional mobility in persons with multiple sclerosis.","volume":"97","author":"Sebasti\u00e3o","year":"2016","journal-title":"Arch Phys Med Rehabil"},{"key":"R39-20260522","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/09638288.2019.1617793","article-title":"The adaptation and validation of a stigma measure for individuals with multiple sclerosis.","volume":"43","author":"Eldridge-Smith","year":"2021","journal-title":"Disabil Rehabil"},{"key":"R40-20260522","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The multiple sclerosis impact scale (MSIS-29) a new patient-based outcome measure.","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"R41-20260522","first-page":"62","article-title":"Cross-cultural adaptation of the multiple sclerosis impact scale (msis-29) for iranian ms patients, evaluation of reliability and validity.","volume":"64","author":"Ayatollahi","year":"2006","journal-title":"Tehran Univ Med Sci J"},{"key":"R42-20260522","doi-asserted-by":"crossref","first-page":"e0177230","DOI":"10.1371\/journal.pone.0177230","article-title":"Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.","volume":"12","author":"Seok","year":"2017","journal-title":"PLoS One"},{"key":"R43-20260522","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12883-023-03162-1","article-title":"Impact of dysautonomic symptom burden on the quality of life in neuromyelitis optica spectrum disorder patients.","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Neurol"},{"key":"R44-20260522","doi-asserted-by":"crossref","first-page":"103332","DOI":"10.1016\/j.msard.2021.103332","article-title":"Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: insights from the SAkura studies.","volume":"57","author":"Levy","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R45-20260522","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/13854046.2012.694912","article-title":"Validity and reliability of a Persian translation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).","volume":"26","author":"Eshaghi","year":"2012","journal-title":"Clin Neuropsychol"},{"key":"R46-20260522","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.msard.2017.08.006","article-title":"Deconstructing the symbol digit modalities test in multiple sclerosis: the role of memory.","volume":"17","author":"Patel","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"R47-20260522","doi-asserted-by":"crossref","first-page":"102950","DOI":"10.1016\/j.msard.2021.102950","article-title":"The Symbol Digit Modalities Test (SDMT) is sensitive but non-specific in MS: lexical access speed, memory, and information processing speed independently contribute to SDMT performance.","volume":"51","author":"Sandry","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R48-20260522","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/da.20070","article-title":"Psychometric properties of a Persian\u2010language version of the Beck Depression Inventory\u2010Second edition: BDI\u2010II\u2010PERSIAN.","volume":"21","author":"Ghassemzadeh","year":"2005","journal-title":"Depress Anxiety"},{"key":"R49-20260522","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1037\/1040-3590.10.2.83","article-title":"A psychometric evaluation of the Beck Depression Inventory\u2013II.","volume":"10","author":"Dozois","year":"1998","journal-title":"Psychol Assess"},{"key":"R50-20260522","first-page":"136","article-title":"Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI).","volume":"66","author":"Kaviani","year":"2008","journal-title":"Tehran Univ Med J"},{"key":"R51-20260522","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties.","volume":"56","author":"Beck","year":"1988","journal-title":"J Consult Clin Psychol"},{"key":"R52-20260522","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus.","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"key":"R53-20260522","first-page":"974","article-title":"Fatigue severity scale: the psychometric properties of the persian-version in patients with multiple sclerosis.","volume":"4","author":"Azimian","year":"2009","journal-title":"Res J Biol Sci"},{"key":"R54-20260522","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/NXI.0000000000000985","article-title":"Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody\u2013seropositive patients.","volume":"8","author":"Ayzenberg","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R55-20260522","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"R56-20260522","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.msard.2018.04.009","article-title":"Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: the first report from Iran.","volume":"22","author":"Barzegar","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"R57-20260522","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","article-title":"Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community.","volume":"17","author":"Eaneff","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"R58-20260522","doi-asserted-by":"crossref","first-page":"e0224419","DOI":"10.1371\/journal.pone.0224419","article-title":"Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis.","volume":"15","author":"Masuda","year":"2020","journal-title":"PLoS One"},{"key":"R59-20260522","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3988\/jcn.2023.0328","article-title":"Usefulness of the MFIS-K, FSS, and FACIT-F fatigue scales in Korean patients with MS, NMOSD, and MOGAD.","volume":"20","author":"Ju","year":"2024","journal-title":"J Clin Neurol"},{"key":"R60-20260522","doi-asserted-by":"crossref","DOI":"10.1037\/sah0000599","article-title":"The experience of stigma and concealment in multiple sclerosis.","author":"Maguire","year":"2024","journal-title":"Stigma Health"},{"key":"R61-20260522","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/13524585231223057","article-title":"Association between demographics, socioeconomics, and disease-related factors and the perception of stigma in people with MS.","volume":"30","author":"Ghajarzadeh","year":"2024","journal-title":"Mult Scler"},{"key":"R62-20260522","doi-asserted-by":"crossref","first-page":"214","DOI":"10.7224\/1537-2073.2017-108","article-title":"Association of unemployment and informal care with stigma in multiple sclerosis: evidence from the survey on living with neurological conditions in Canada.","volume":"21","author":"Hategeka","year":"2019","journal-title":"Int J MS Care"},{"key":"R63-20260522","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1017\/S0033291721003597","article-title":"Self-processing in relation to emotion and reward processing in depression.","volume":"53","author":"Hobbs","year":"2023","journal-title":"Psychol Med"},{"key":"R64-20260522","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.genhosppsych.2013.12.011","article-title":"Point prevalence and correlates of depression in a national community sample with multiple sclerosis.","volume":"36","author":"Viner","year":"2014","journal-title":"Gen Hosp Psychiatry"},{"key":"R65-20260522","first-page":"1","article-title":"Perceived social stigma in patients with multiple sclerosis: a study from Iran.","volume":"27","author":"Kalantari","year":"2018","journal-title":"Acta Neurol Taiwan"},{"key":"R66-20260522","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.socscimed.2018.01.015","article-title":"Judgment hurts: the psychological consequences of experiencing stigma in multiple sclerosis.","volume":"208","author":"Cadden","year":"2018","journal-title":"Soc Sci Med"},{"key":"R67-20260522","doi-asserted-by":"crossref","first-page":"105007","DOI":"10.1016\/j.msard.2023.105007","article-title":"The prevalence of depression, anxiety, and sleep disturbances in patients with neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis.","volume":"79","author":"Liu","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"R68-20260522","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-016-0621-4","article-title":"Determinants of stigma in a cohort of Hellenic patients suffering from multiple sclerosis: a cross-sectional study.","volume":"16","author":"Anagnostouli","year":"2016","journal-title":"BMC Neurol"},{"key":"R69-20260522","doi-asserted-by":"crossref","first-page":"102261","DOI":"10.1016\/j.msard.2020.102261","article-title":"Anxiety and depression in multiple sclerosis (MS): antecedents, consequences, and differential impact on well-being and quality of life.","volume":"44","author":"Hanna","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R70-20260522","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0730-1","article-title":"Health-related quality of life among adults with diverse rare disorders.","volume":"12","author":"Bogart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"R71-20260522","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pathophys.2010.04.008","article-title":"Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis.","volume":"18","author":"Kira","year":"2011","journal-title":"Pathophysiology"},{"key":"R73-20260522","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2011.08.043","article-title":"Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders.","volume":"311","author":"Kira","year":"2011","journal-title":"J Neurol Sci"},{"key":"R74-20260522","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpsychores.2019.05.001","article-title":"The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson\u2019s disease and Huntington\u2019s disease: two meta-analyses.","volume":"122","author":"Ghielen","year":"2019","journal-title":"J Psychosom Res"},{"key":"R75-20260522","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/papt.12321","article-title":"Psychological interventions for people with Parkinson\u2019s disease in the early 2020s: where do we stand?","volume":"94","author":"Zarotti","year":"2021","journal-title":"Psychol Psychother"},{"key":"R76-20260522","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ps.53.9.1125","article-title":"Effects of psychoeducation for Korean Americans with chronic mental illness.","volume":"53","author":"Shin","year":"2002","journal-title":"Psychiatr Serv"},{"key":"R77-20260522","first-page":"21","article-title":"The effectiveness of acceptance and commitment group therapy to improving the quality of life in patients with multiple sclerosis.","volume":"10","author":"Parsa","year":"2018","journal-title":"J Clin Psychol"},{"key":"R78-20260522","first-page":"7","article-title":"Effectiveness of acceptance and commitment therapy on psychological distress, marital satisfaction and quality of life in women with multiple sclerosis.","volume":"19","author":"Shakernegad","year":"2017","journal-title":"J Health Care"},{"key":"R79-20260522","doi-asserted-by":"crossref","first-page":"103647","DOI":"10.1016\/j.msard.2022.103647","article-title":"Health-related quality of life in neuromyelitis optica spectrum disorder patients in an Argentinean cohort.","volume":"59","author":"Contentti","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R80-20260522","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin\u20104 autoimmunity and neuromyelitis optica spectrum.","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:01:06Z","timestamp":1779433266000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":79,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046738","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"2025-05-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}